Market Size of Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Analysis
The Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market size is estimated at USD 0.3 billion in current year, and is expected to reach USD 0.5 billion by forecast period, growing at a CAGR of 9% during the forecast period.
The COVID-19 pandemic has been testing the capacity to respond and adapt to populations, governments, and health systems worldwide. In the Latin America region, Brazil presented the first suspected and the first confirmed cases. Most Latin American countries failed to implement timely measures to protect individuals with diabetes, which may severely impact individuals, health systems, and economies.
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.
The COVID-19 pandemic benefited the Sodium-Dependent Glucose Cotransporter 2 market. Diabetes weakens the immune system, which is exacerbated by COVID-19. Diabetes patients are more likely to have significant problems than non-diabetics. During COVID-19, diabetic medicine manufacturers took care to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. Novo Nordisk stated that Since the outbreak of COVID-19, their commitment to patients, staff and the communities in which they operate has not changed, and they will continue provide their medicines and devices to people with diabetes and other serious chronic conditions, protect the health of their employees, and support doctors and caregivers in the fight against COVID-19 in Latin America.
